Genotoxicity and Carcinogenicity Studies of Soy Isoflavones
- 1 July 2002
- journal article
- research article
- Published by SAGE Publications in International Journal of Toxicology
- Vol. 21 (4) , 277-285
- https://doi.org/10.1080/10915810290096441
Abstract
The potential cancer preventive efficacy of soy isoflavones is being investigated in preclinical and phase 1 clinical studies sponsored by the U.S. National Cancer Institute. Although 90-day oral toxicity studies with PTI G-2535 (an investigational soy isoflavone drug product) in rats and dogs, as well as teratology studies, indicated no signs of toxicity, there remains a mechanistic concern associated with the ability of isoflavones (i.e., genistein) to inhibit topoisomerase, possibly leading to DNA strand breaks. The present report describes results from two in vitro genotoxicity studies, one in vivo genotoxicity study, and a single carcinogenicity study conducted in p53 knockout mice. Bacterial mutagenesis experiments using six tester strains without metabolic activation revealed no evidence that PTI G-2535 was mutagenic. In similar experiments with exogenous metabolic activation there were statistically significant increases in revertants, but less than twofold, in a single (Salmonella typhimurium TA100) tester strain. Mouse lymphoma cell mutagenesis experiments conducted with and without metabolic activation revealed statistically significant increases in mutation frequency at PTI G-2535 concentrations ≥ 0.8 and 12 μg/ml, respectively; such increases were dose related and increases in the frequency of both small and large colonies were observed. A statistically significant increase in the frequency of micronucleated polychromatic erythrocytes was also seen 24 hours after treatment in male, but not female, mice who received 500 and 1000 mg/kg body weight PTI G-2535; however, such increases were small, were not dose related, and were not observed 48 hours after treatment. In contrast, dietary genistein had no effect on survival, weight gain, or the incidence or types of tumors that developed in cancer-prone rodents lacking the p53 tumor suppressor gene, p53 knockout mice. The apparent risk/benefit of isoflavone ingestion may ultimately depend on the dose and developmental timing of exposure.Keywords
This publication has 38 references indexed in Scilit:
- Genistein: does it prevent or promote breast cancer?Environmental Health Perspectives, 2000
- p53‐independent Induction of p21 (WAF1/CIP1), Reduction of Cyclin B1 and G2/M Arrest by the Isoflavone Genistein in Human Prostate Carcinoma CellsJapanese Journal of Cancer Research, 2000
- Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the ratCarcinogenesis: Integrative Cancer Research, 1998
- Infant Cancer in the U.S.Journal of Pediatric Hematology/Oncology, 1997
- Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesisThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Regulation of sex hormone-binding globulin production by isoflavonoids and patterns of isoflavonoid conjugation in HepG2 cell culturesSteroids, 1995
- Xenoestrogens alter mammary gland differentiation and cell proliferation in the rat.Environmental Health Perspectives, 1995
- Soy intake and cancer risk: A review of thein vitroandin vivodataNutrition and Cancer, 1994
- Spontaneous and carcinogen–induced tumorigenesis in p53–deficient miceNature Genetics, 1993
- Effect of genistein on topoisomerase activity and on the growth of [VAL 12]Ha-ras-transformed NIH 3T3 cellsBiochemical and Biophysical Research Communications, 1988